News

GSK’s MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical study Derma. To be

Intas intends to launch a double-blind, placebo-controlled Phase 3 clinical trial of ABI’s orally administered interferon-alpha lozenges in India before the end of March. The study will involve

The new Thermo Scientific Accela 1250 pump features Force Feedback Control (FFC) which eliminates the need for pulse dampening while improving flow accuracy and gradient precision under extreme

The new SEZ center represents a strategic investment for Kendle and demonstrates its commitment to further invest in Asia/Pacific to meet customer needs. The new unit is expected

The Tropic trial compared the combination of Cabazitaxel plus prednisone / prednisolone to the active agent mitoxantrone plus prednisone / prednisolone. For many patients with metastatic hormone-refractory prostate

Humacyte’s vascular graft is based on its proprietary platform technology for engineering human, extracellular matrix-based tissues having properties analogous to native tissues. The company’s vascular grafts will first

The audit was performed as part of the Ministry of Health’s evaluation of Protalix’s manufacturing process of taliglucerase alfa for the treatment of Gaucher disease. Earlier, in February

FDA determined that Vyvanse qualified as an NCE within the meaning of the governing statutes and regulations. As an NCE, Vyvanse is entidtled to 5-year market exclusivity. The

The appeal Celgene expects to file will detail that Vidaza as a treatment for MDS meets not only the end of life criteria (as set out by the